Dusopharm, pills 50mg, 30pcs

Composition

Active ingredient:

naphthidrofuryl oxalate 50 mg;

Auxiliary substances:

lactose monohydrate,

microcrystalline cellulose,

wheat starch,

copovidone,

colloidal silicon dioxide,

magnesium stearate,

talc;

Shell:

titanium dioxide, talc, magnesium stearate, macrogol 6000, methacrylic acid and ethyl acrylate copolymer, dye sunset yellow (E 110)

Pharmacological action

Duzofarm is a drug that improves cerebral and peripheral blood circulation. It has a vasodilating effect. Reduces OPSS and increases the minute volume of the heart, without significantly affecting the heart rate and blood pressure. The vasodilating effect of Dusopharm is the result of its direct myotropic action, antagonistic to serotonin 5 HT2 receptors and alpha-adrenoblocking action.

It has a m-holinoblokiruyushchy effect. It has a positive effect on cellular metabolism, improving the utilization of oxygen and glucose. This effect of the drug is due to its ability to increase the level of ATP and inhibit the enzyme succinate dehydrogenase. Activates glucose utilization through the citric acid cycle and increases the conversion of succinic acid to fumaric acid. As a result, the resistance of cells (including the brain) to hypoxia increases. In addition, Dusopharm reduces the increased blood viscosity.

Pharmacokinetics

Absorption

Dusopharm is almost completely absorbed when taken orally. Food has almost no effect on its absorption. After taking a single dose of 100 mg, Cmax is observed in 45-60 minutes and is 175 mcg / ml. It undergoes hepatic recirculation, which contributes to its longer presence in the plasma.

Linking

Binding to blood proteins is 80%. Penetrates through the BBB. Cmax in brain tissues is reached in 60 minutes. 24 hours after use, its concentration in the brain tissue is 3 times higher than in plasma. There are no data on the penetration of Dusopharm through the placenta and into breast milk.

Metabolism

It is mainly metabolized in the liver by hydrolysis, which is carried out by plasma esterases. The main metabolites studied are naphronic acid and diethylaminoethanol, which has a stimulating effect on the central nervous system.

Elimination

of T1 / 2 is 1-2 hours with a single dose of 100 mg and 3.5 hours with a dose of 200 mg. It is excreted from the body mainly through the intestines and in a small amount by the kidneys.

Pharmacokinetics in special clinical cases

There are no data on changes in the rate of its excretion in patients with impaired liver or kidney function.

Age does not affect the pharmacokinetic parameters of the drug.

Indications

Recovery period of cerebral circulatory disorders; peripheral circulatory disorders (intermittent claudication, Raynaud’s disease, trophic ulcers).

Contraindications

• myocardial infarction (acute phase);
• hypotension;
• hemorrhagic stroke (acute phase);
• epilepsy;
• increased convulsive readiness;
• chronic heart failure II-III stage (III-IV functional class NYHA classification);
• tachyarrhythmia;
• age to 18 years (efficacy and safety not established);
• – increased individual sensitivity to the drug.

With caution, the drug should be prescribed for angle-closure glaucoma, prostatic hyperplasia.

Side effects

From the digestive system:  nausea, vomiting, epigastric pain, intestinal colic, diarrhea, decreased appetite, reversible increases in liver enzyme activity, ulcers of the gastric mucosa.

From the central nervous system:  headache, dizziness, sleep disturbance.

Other services:  allergic reactions.

Interaction

Increases the antihypertensive effect of antihypertensive drugs. In this regard, more frequent monitoring of blood pressure is recommended at the beginning of treatment with Dusopharm and antihypertensive agents simultaneously.

How to take, course of use and dosage

The drug is prescribed inside. Tablets are swallowed whole, washed down with a sufficient amount of liquid (water).

In case of cerebral circulatory disorders, the drug is prescribed in a daily dose of 300 mg (2 tablets 3 times a day).

In case of peripheral circulatory disorders, the daily dose is 500-600 mg, divided into 3 doses.

Duzopharm is recommended for long-term therapy (up to 6 months).

No dose adjustment is required in patients with renal or hepatic insufficiency.

Overdose

Symptoms:  increased severity of side effects, ventricular arrhythmia, anxiety, decreased blood pressure, bradycardia.

Treatment:  gastric lavage, use of activated charcoal and laxatives, symptomatic treatment. There is no specific antidote.

Composition

Tablet Form of production

Storage conditions

The drug should be stored in a dry place, protected from light, inaccessible to children at a temperature not exceeding 25°C.

Shelf life

3 years

Active ingredient

Naftidrofuryl

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults

Indications

Trophic Ulcers, Cerebral Circulation Disorders, Raynaud ‘s disease